Gen­mab gains on promis­ing ear­ly suc­cess for dara­tu­mum­ab PhI­II in mul­ti­ple myelo­ma, but ques­tions linger

Shares of Copen­hagen-based Gen­mab surged Thurs­day morn­ing as in­ves­ti­ga­tors de­clared that its late-stage com­bo drug us­ing dara­tu­mum­ab (Darza­lex) hit the pri­ma­ry end­point for treat­ing mul­ti­ple …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER